200230 — Telcon RF Pharmaceutical Income Statement
0.000.00%
Last trade - 00:00
- KR₩87bn
- KR₩105bn
- KR₩36bn
- 11
- 55
- 13
- 11
R2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | ARS | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 52,478 | 33,141 | 37,841 | 27,830 | 36,307 |
Cost of Revenue | |||||
Gross Profit | 14,857 | 7,292 | 9,125 | 5,664 | 9,587 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 67,478 | 77,194 | 43,494 | 49,298 | 36,666 |
Operating Profit | -15,000 | -44,053 | -5,653 | -21,468 | -359 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -52,776 | -43,813 | -22,875 | -42,117 | 13,949 |
Provision for Income Taxes | |||||
Net Income After Taxes | -52,776 | -43,832 | -22,875 | -42,117 | 13,949 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -52,649 | -43,054 | -23,098 | -42,084 | 13,906 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -52,649 | -43,054 | -23,098 | -42,084 | 15,330 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -492 | -179 | -226 | -233 | 111 |
Dividends per Share |